## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors propose a machine learning method that leverages AlphaFold-predicted three-dimensional protein structures to predict the functional impacts of genomic variants, specifically focusing on transcriptional pathway perturbations for two proto-oncogenes, NFE2L2 (NRF2) and c-Myc. They report classifiers achieving accuracies above 80% and identify key protein regions associated with significant pathway activity changes.
- **Visible evidence base** Abstract text only; no methodological details, dataset descriptions, performance metrics beyond accuracy, or validation results are provided
- **Missing materials affecting confidence** Full methods, training and test datasets, variant annotations, classifier architectures, cross-validation procedures, baseline comparisons, statistical significance tests, and any figures or tables

## Reviewer
- **Overall assessment** The abstract presents a potentially valuable application of AlphaFold structures to variant effect prediction, an area of growing importance in genomic medicine. However, the current evidence base is insufficient to evaluate the technical soundness, generalizability, or novelty of the approach. The reported accuracy figures lack context, and the absence of methodological detail precludes assessment of potential overfitting, data leakage, or selection bias. The claim that this addresses a gap in computational variant prediction is overstated given existing literature on variant effect predictors.
- **Who would be interested in the results, and why** Researchers in clinical genomics, variant interpretation, and computational biology would be interested if the method demonstrates robust performance beyond the two tested genes. Those working on functional annotation of VUS and on integrating structural information into variant prioritization pipelines would find this relevant. However, the narrow scope to two proto-oncogenes limits immediate broad applicability.
- **Major strengths** The use of AlphaFold-predicted structures for variant impact prediction is a timely and conceptually interesting direction. Focusing on downstream transcriptional pathway activity rather than binary pathogenicity calls is a more nuanced and biologically meaningful target. The identification of specific protein regions linked to pathway perturbations could offer mechanistic insights.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The abstract does not provide sufficient evidence to establish that the method is technically sound, generalizable, or superior to existing approaches. Key technical details are absent, and the reported accuracy alone is not convincing without context on baselines, data splits, and statistical rigor.
- **Assessment against Nature-style criteria** Originality: Moderate. The idea of using AlphaFold structures for variant effect prediction is not entirely new, and the abstract does not clearly differentiate this work from existing structure-based predictors. Scientific importance: Potentially high if validated, but the narrow scope to two genes limits immediate impact. Interdisciplinary readership: The abstract is accessible to computational biologists and genomicists, but the lack of methodological detail may deter structural biologists and clinicians. Technical soundness: Not assessable from the abstract alone; the absence of validation details is a critical gap. Readability for nonspecialists: The abstract is reasonably clear but uses jargon (e.g., "transcriptional activities") without sufficient explanation.
- **Recommendation posture** Currently not established from the provided evidence. The abstract is intriguing but does not provide enough information to support the core claims. A full manuscript with rigorous validation would be required to assess whether the method is sound and impactful.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** The authors claim that "machine learning classifiers" achieve "accuracies higher than 80%" for predicting protein regions impacting transcriptional activities of NRF2 and c-Myc.
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract reports accuracy values without specifying the dataset size, class balance, cross-validation scheme, or the baseline against which these accuracies are compared. Accuracy is a misleading metric when classes are imbalanced, which is likely in variant effect prediction where pathogenic variants are rare. No information is given on precision, recall, F1-score, or area under the ROC curve.
- **Why it matters** Without these details, the reported accuracies cannot be interpreted. High accuracy on a skewed dataset may reflect trivial performance, such as predicting the majority class. The absence of baseline comparisons (e.g., against PolyPhen, SIFT, or other structure-based predictors) means the claimed advantage is unsubstantiated.
- **Resolution test** Provide a detailed description of the dataset, including variant counts, class distribution, and source. Report multiple performance metrics (precision, recall, F1, AUC) with confidence intervals. Compare against at least one established variant effect predictor on a held-out test set.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Generalizability and external validity
- **Claim pointer** The authors state that the method predicts "how a variant will influence changes to a gene's downstream biological pathways," implying a generalizable approach.
- **Evidence pointer** Abstract only; location not provided
- **Concern** The method is trained and evaluated on only two proto-oncogenes, NRF2 and c-Myc. The abstract does not mention any external validation on independent datasets, other genes, or experimental confirmation of predicted pathway perturbations. The claim of generalizability to "genome variation" broadly is not supported by evidence from two genes.
- **Why it matters** Variant effects are highly context-dependent, and a method that works for two transcription factors may not transfer to other protein classes, such as enzymes, receptors, or structural proteins. Without external validation, the risk of overfitting to the specific features of these two genes is high.
- **Resolution test** Validate the method on a diverse set of genes with known variant effects and experimentally confirmed pathway outcomes. Report performance stratified by protein function class. If external validation is not feasible, clearly state the method's scope as a proof-of-concept limited to the tested genes.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Novelty and positioning
- **Claim pointer** The authors state that "There are few, if any, computational methods for variants comparable to biological activity predictions," implying a gap in the field.
- **Evidence pointer** Abstract only; location not provided
- **Concern** This claim is inaccurate. Numerous computational methods predict variant effects on protein function, including structure-based approaches (e.g., FoldX, Rosetta), sequence-based predictors (e.g., PolyPhen, SIFT, CADD), and methods that integrate AlphaFold structures (e.g., AlphaMissense). The abstract does not acknowledge or compare against these existing tools.
- **Why it matters** Overstating the novelty undermines the credibility of the work. A proper comparison with existing methods is essential to demonstrate that the proposed approach offers a meaningful advance, not just an incremental variation.
- **Resolution test** Revise the claim to accurately reflect the state of the field. Include a systematic comparison with at least two established variant effect predictors on the same benchmark dataset, showing where the proposed method improves or complements existing tools.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity and terminology
- **Affected element** Abstract text
- **Evidence pointer** Abstract; location not provided
- **Issue** The term "transcriptional activities" is used without defining what is measured or how it is quantified. The abstract also refers to "protein regions" without clarifying whether these are domains, motifs, or residue-level features.
- **Required correction** Define "transcriptional activities" operationally (e.g., reporter gene assays, RNA-seq readouts) and specify the granularity of "protein regions" (e.g., residues, secondary structure elements, domains).

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Reproducibility
- **Affected element** Method description
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract does not mention the software, code availability, or data availability. For a machine learning method, reproducibility is critical.
- **Required correction** State in the abstract or full manuscript that code and data will be made publicly available, with a link or repository identifier.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Statistical rigor
- **Affected element** Performance reporting
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract reports "accuracies higher than 80%" without confidence intervals or statistical significance tests. It is unclear whether the difference from a null model is significant.
- **Required correction** Report confidence intervals for accuracy and include a statistical test (e.g., McNemar's test) comparing against a baseline classifier.

## Risk / unsupported claims
- The claim that the method predicts "functional impacts of genome variation" broadly is unsupported, as only two genes are tested.
- The claim that "there are few, if any, computational methods for variants comparable to biological activity predictions" is inaccurate and not supported by the abstract.
- The reported accuracies are uninterpretable without dataset details, baselines, and additional metrics.
- The generalizability of the method to other genes or variant types is not established.
- The use of AlphaFold structures is mentioned but not justified; no evidence is provided that structural features improve predictions over sequence-based features alone.